Pharmaceutical composition and a process thereof

ABSTRACT

The present invention relates to a pharmaceutical composition having dopaminergic activity and other related pharmaceutical activities comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s); a process of preparing a pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s), wherein the process comprising steps of: (a) extracting a clear solution containing trigonelline and 4-hydroxyisoleucine from plant source; and (b) optionally precipitating derivative(s) of trigonelline and 4-hydroxyisoleucine from the clear solution and obtaining said composition; and an in-vitro method to increase levels of dopamine or to inhibit prolactin by allowing composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s) to bind to cell receptors.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional PatentApplication No. 60/893,075 filed on Mar. 5, 2007 all of which is hereinincorporated by reference in its entirety.

FIELD OF THE INVENTION

This invention relates to a novel composition and a preparation thereoffrom natural sources. This invention also relates to the application ofa novel composition as a Dopaminergic agent with applications in themanagement of dopamine related disorders including Parkinson's disease.

This invention also relates to applications associated with a decreaseof prolactin as a prolactin-inhibiting compound, a muscle relaxant, todecrease side-effects caused by anti-psychotic drugs, to decrease sexualdysfunction caused by increased Prolactin and as a compound, whichenhances mental alertness.

BACKGROUND AND PRIOR ART OF THE INVENTION

Dopamine is a hormone and a neurotransmitter present in both vertebratesand invertebrates. Chemically it is a phenethylamine present in thebrain and acts as a neurotransmitter which activates specific dopaminereceptors (D1-D5). Dopamine has many functions in the brain, includingimportant roles in behavior and cognition, motor activity, motivationand reward, regulation of milk production, sleep, mood, attention, andlearning. Dopamine plays a major role in appetite, Sociability,Salience, Behavior disorders, Latent inhibition and creative drive.Dopamine is also involved in regulating prolactin secretion.

Inadequate levels of dopamine trigger symptoms like tremors, rigidityand bradykinesia (slowness of movement). In healthy subjects, neuronsproduce and release dopamine in the brain and other parts of the body.When the dopamine is released by one neuron, it is received by thereceptors of the next neuron. This chain reaction eventually leads tothe stimulation of nerves. Various neurological disorders can interferewith dopamine production and cause the dopamine levels in the brain todrop. Abnormal levels of dopamine also cause a number of disorders, someof which are chronically degenerative (like Parkinson's disease).

Dopamine strongly influences both motor and thinking areas of the brain.One type of Dopamine works in the movement and motor system. When levelsof dopamine decrease below the “normal range” motor and gross-movementproblems set in. Very low levels of Dopamine in the motor areas of thebrain are known to produce Parkinson's Disease with symptoms such as:muscle rigidity and stiffness, stooped/unstable posture, loss of balanceand coordination, gait (walking pattern) disturbance, slow movements anddifficulty with voluntary movements, Small-step gait/walking, aches inmuscles, tremors and shaking, fixed, mask-like facial, expression, slow,monotone speech, impairment of fine-motor skills, falling when walkingand an impairment in cognitive/intellectual ability

Low levels of dopamine impair the ability to focus on an environment orto “lock on” to tasks, activities, or conversations. Low levels ofDopamine make concentration and focus very difficult and are alsoassociated with Attention-Deficit Hyperactivity Disorder (ADHD).

Dopamine also plays a major role in inhibiting prolactin secretion.Prolactin is a peptide hormone secreted by the lactotroph cells in thepituitary gland. Prolactin plays a major role in inducing lactation andsexual gratification (which is caused by low levels for dopamine.Adequate levels of dopamine are required for sexual arousal). Dopamineserves as the major prolactin-inhibiting factor and is secreted intoportal blood by hypothalamic neurons, binds to receptors on lactotrophs,and inhibits both the synthesis and secretion of prolactin. Increasedlevels of prolactin have many ill effects like infertility, polycysticovary syndrome (PCOS), headaches, reduced sex drive and vision problems.High prolactin levels are caused due to many factors including physicaland mental stress. Hence a dopaminergic compound (one that increasesdopamine levels) will play a key role in regulating (limiting) thelevels of prolactin thereby managing the various effects of high levelsof prolactin.

It is found that chronic and strenuous exercise as practiced byathletes, body builders and sportsman also leads to an increase inprolactin level. This increased prolactin decreases their sexual libidoand induces sexual dysfunction. Therefore dopaminergic agents can beused for decreasing the levels of prolactin and thereby eliminating theside effects by maintaining this hormone within physiological limits.

Dopaminergic agents can be used as a muscle relaxant as it inhibits theexcitation caused by acetylcholine. Therefore the Dopaminergic substanceof this invention can be used as a muscle relaxant in exercisephysiology, anesthesia and in case of muscle spasms.

One of the major effects of low levels of dopamine is MovementDisorders. Movement disorders are a group of diseases and syndromesaffecting the ability to produce and control movement. To produce anyform of movement even simple motions requires the coordination andaction of a complex network of signals. Disruption of any portion ofthis system can cause a person to produce movements that are too weak,too forceful, too uncoordinated, or too poorly controlled for the taskat hand. Unwanted movements may occur at rest or intentional movementsmay become impossible. Such conditions are called movement disorders.

In some cases, the abnormal movements are the only symptoms of lowlevels of dopamine. Disorders causing abnormal movements include:Parkinson's disease, Parkinsonism caused by drugs or poisons,Parkinson-plus syndromes (progressive supranuclear palsy, multiplesystem atrophy, and cortical-basal ganglionic degeneration).

These disorders are caused due to a lack or excess of theneurotransmitter Dopamine. Drug therapy can help compensate for someimbalances of the basal ganglionic circuit. Acetylcholine is anexcitatory chemical that helps regulate dopamine in the brain. In thebody, acetylcholine released at nerve endings causes muscle contraction.

Parkinson's is a progressive degenerative disease, which destroysdopamine-producing cells and leads to a problem in coordinated movement.It is characterized by tremor, rigidity, Akinesia and posturalinstability. The main biochemical abnormality is the depletion inDopamine and which causes an imbalance between acetylcholine anddopamine. Causes of Parkinson's are not known clearly. There is weakhereditary link in few cases. It is also caused by an environmentaltoxin MPTP (Methyl phenyl tetra-hydro pyridine), which is used as apesticide.

Parkinson's disease is usually a disorder of the elderly occurring afterthe age of 65. It is caused by the death of a group of nerve cells inthe brain called the “Substantia Nigra” or black substance because theylook dark in appearance. The nerve process from these cells normallyextends up to another area of brain called the striatum, where they makeconnections and release a chemical called Dopamine as theirNeurotransmitter.

The Substantia Nigra and the striatum help to control movement,including our ability to initiate movement. With the loss of theNigrostriatal pathway, the Parkinson's patient has extreme difficulty inperforming such acts like getting out of a chair and starting to walk.They also experience increased tremor and rigid muscles.

Current methods of treatment for dopamine related diseases (eg:Parkinson's and diseases related to low levels of dopamine) include:

L-Dopa (Dihydroxy Phenyl Alanine)

Since the cause of Parkinson's disease is a loss of Dopamine releasingnerve cells, one approach to treating this disorder is to restore thelevels of Dopamine in the brain. Dopamine will not pass from the bloodinto the brain. Within nerve cells, dopamine is produced by a series ofchemical reactions catalyzed by enzymes. The last stage in the sequenceis the formation of dopamine from the amino acid L-Dopa. L-Dopa easilycrosses into the brain from blood. The most popular and effectivetreatment for Parkinson's is the administration of L-Dopa in tabletform.

L-Dopa gets into blood stream and passes into brain. In the brain Dopadecarboxylase converts this into Dopamine. L-Dopa produces a very markedimprovement in general movement, facial expression and body posture.However, it has very poor effect on tremor, swallowing, balance and theslow initiation of movements.

Combining Other Drugs with L-Dopa

The enzyme Dopa Decarboxylase that converts L-Dopa to Dopamine exists inblood and body tissues. Therefore, L-Dopa degrades in the serum to theextent of 90%. This is blocked by inhibiting this enzyme by other drugslike Carbidopa and Benseraside. These are combined with L-Dopa toincrease its brain availability. Carbidopa and Benseraside do not passinto the brain.

Tolcapone and Entacalpone

L-Dopa is also destroyed by another enzyme COMT (Catechol O-MethylTransferase). These drugs inhibit COMPT and make L-Dopa available tobrain. But these drugs have long term problem with L-Dopa. On long termadministration of L-Dopa, patients may experience fluctuations in itseffect. There may be greater delay in the onset of action and drugaction period may get shortened. Patients also experience on offperiods. This implies that the patients may function perfectly well forlong hours after the drug administration and they might find that theeffect of the drug stops abruptly.

Side effects of L-Dopa: Most patients feel nausea; prolonged use of thiscan induce Schizophrenia, especially hallucinations and disturbed sleep.Continued use also leads to slow and involuntary movements.

MAO Inhibitions (Monoamine Oxidase)

An alternative to increasing the formation of dopamine in the brain isby administering L-Dopa to decrease the breakdown of dopamine. Dopamineis broken down by an enzyme Monoamine Oxidase (MAO), particularly MAO-B.Deprenyl is a MAO-B inhibiting.

Receptor Agonists

It is possible to compensate for the loss of Dopamine by using drugswhich act directly on Dopamine receptors. Drugs like Bromocriptine,Lisuride are Receptor Agonists. They stimulate the receptors whichrespond to dopamine and act as replacements for the Dopamine normallyreleased by the Nigrostriatal neurons. These drugs induce a range ofinvoluntarily movements and act on dopamine receptors in the pituitarygland, a part of the brain, which controls many important hormonesecretions. The side effects of the activation of Dopamine receptors tosuppresses the release of the hormone prolactin are infertility andmenstrual disorders.

Anticholinergic Drugs

Within the striatum of the brain, both dopamine and Acetylcholine areneurotransmitters. Dopamine causes inhibition of nerve cells whileacetylcholine causes their excitation. When the brain loses Dopaminecells, the activity of acetylcholine is intact. Therefore one strategyis to reduce acetylcholine and balance its effect along with the effectof Dopamine. Anticholinergic drugs are more effective in reducingtremors, although they have no effect on muscular rigidity anddifficulty of movement. These drugs have many side effects like drymouth, blurred vision, constipation, difficulty in urination etc.

U.S. Pat. No. 4,880,816 describes a compound where dopamine ischemically combined to another molecule DHC, particularly of atrigonelline which has blood brain barrier penetration property. Here,DHC compounds acts as an adjunct to dopamine to cross the blood brainbarrier and gets broken and eliminated. Thus, it does not define anydopaminergic action for trigonelline.

Current therapy targets symptomatic relief and no agent is capable ofinhibiting neuronal degeneration. There is urgent need for a kinder andgentler therapy for long-term management with minimal side effect andwith optimum efficiency. The present invention addresses this urgentneed for a Dopaminergic product, which can be effectively utilized forthe management of diseases associated with the lack of dopamineincluding Parkinson's disease.

A major disadvantage of anti-psychotic drugs is their blocking the D2receptor of dopamine. Thus these drugs lead to the side effect ofmovement disorders linked to blockage of dopamine receptor D2 in thebrain. Hence a dopaminergic agent would be the answer to the immobilitycaused as a side effect of anti-psychotic drugs.

OBJECTS OF THE INVENTION

The main object of the present invention is to obtain a pharmaceuticalcomposition having dopaminergic activity and other relatedpharmaceutical activities.

Another main object of the present invention is to obtain apharmaceutical composition comprising trigonelline or its derivative(s)and 4-hydroxyisoleucine or its derivative(s) optionally along withexcipients(s).

Yet another object of the present invention is to develop a process ofpreparing a pharmaceutical composition comprising trigonelline or itsderivative(s) and 4-hydroxyisoleucine or its derivative(s), optionallyalong with excipients(s).

Still another object of the present invention is to extract trigonellineand 4-hydroxyisoleucine from plant source.

Still another object of the present invention is to obtain a method oftreating dopamine related diseases by administering a therapeuticallyeffective amount of a pharmaceutical composition comprising trigonellineor its derivative(s) and 4-hydroxyisoleucine or its derivative(s),optionally along with excipients(s) in a subject in need thereof.

Still another object of the present invention is to obtain a method oftreating ill effects caused by prolactin by administering atherapeutically effective amount of a pharmaceutical compositioncomprising trigonelline or its derivative(s) and 4-hydroxyisoleucine orits derivative(s), optionally along with excipients(s) in a subject inneed thereof.

Still another object of the present invention is to obtain a method oftreating side-effects caused by dopamine receptor antagonists byadministering a therapeutically effective amount of a pharmaceuticalcomposition comprising trigonelline or its derivative(s) and4-hydroxyisoleucine or its derivative(s), optionally along withexcipients(s) in a subject in need thereof.

STATEMENT OF THE INVENTION

Accordingly, the present invention relates to a pharmaceuticalcomposition having dopaminergic activity and other relatedpharmaceutical activities comprising trigonelline or its derivative(s)and 4-hydroxyisoleucine or its derivative(s), optionally along withexcipients(s); a process of preparing a pharmaceutical compositioncomprising trigonelline or its derivative(s) and 4-hydroxyisoleucine orits derivative(s), optionally along with excipients(s), wherein theprocess comprising steps of: (a) extracting a clear solution containingtrigonelline and 4-hydroxyisoleucine from plant source; and (b)optionally precipitating derivative(s) of trigonelline and4-hydroxyisoleucine from the clear solution and obtaining saidcomposition; a method of treating dopamine related diseases, said methodcomprising administering a therapeutically effective amount of apharmaceutical composition comprising trigonelline or its derivative(s)and 4-hydroxyisoleucine or its derivative(s), optionally along withexcipients(s) in a subject in need thereof, a method of treating illeffects caused by prolactin, said method involves prolactin inhibitionby administering a therapeutically effective amount of a pharmaceuticalcomposition comprising trigonelline or its derivative(s) and4-hydroxyisoleucine or its derivative(s), optionally along withexcipients(s) in a subject in need thereof, and a method of treatingside-effects caused by dopamine receptor antagonists, said methodcomprising administering a therapeutically effective amount of apharmaceutical composition comprising trigonelline or its derivative(s)and 4-hydroxyisoleucine or its derivative(s), optionally along withexcipients(s) in a subject in need thereof.

BRIEF DESCRIPTION OF ACCOMPANYING FIGURES

FIG. 1: shows dose dependent response of the test drug in the reductionof catalepsy. The plot indicates IBH-B as the test drug of theinvention. All values for IBH-B (10, 30 or 100)+Hal (0.5) and L-DOPA(10)+Hal (0.5) are significant at P<0.001 and IBH-B (3)+Hal (0.5) isnon-significant as compared with Hal (0.5) at respective time. Treatmentof IBH-B significantly reduced Haloperidol induced catalepsy.

FIG. 2: shows significant decrease in the tremor score by the test drugindicated as IBH-B in the plot.

FIG. 3: shows the effect of test drug on tyramine potentiation (acutestudy).

FIG. 4: shows the effect of test drug on tyramine potentiation (chronicstudy).

FIG. 5: The response curve illustrating the selective inhibition ofMAO-B by the test compound.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a pharmaceutical composition havingdopaminergic activity and other related pharmaceutical activitiescomprising trigonelline or its derivative(s) and 4-hydroxyisoleucine orits derivative(s), optionally along with excipients(s).

In another embodiment of the present invention, the concentration oftrigonelline or its derivative(s) ranges between 30% to 90% and theconcentration of 4-hydroxyisoleucine or its derivative(s) ranges between10% to 30%.

In yet another embodiment of the present invention, the trigonelline isobtained from plant or animal source.

In still another embodiment of the present invention, the trigonellineis obtained from Trigonella foenum graecum and Coffee arabica.

In still another embodiment of the present invention, the derivative(s)of trigonelline are selected from a group comprising hydrochloridederivatives, acetate derivatives, citrate derivatives, benzoatederivatives, salt derivatives and acid derivatives, preferablyhydrochloride derivatives.

In still another embodiment of the present invention, the4-hydroxyisoleucine is obtained from plant source, preferably Trigonellafoenum graecum.

In still another embodiment of the present invention, the derivative(s)of 4-hydroxyisoleucine are selected from a group comprisinghydrochloride derivatives, acetate derivatives, citrate derivatives,benzoate derivatives, salt derivatives and acid derivatives, preferablyhydrochloride derivatives.

In still another embodiment of the present invention, the excipients(s)are selected from a group comprising granulating agents, binding agents,lubricating agents, disintegrating agents, sweetening agents, glidants,anti-adherents, anti-static agents, surfactants, anti-oxidants, gums,coating agents, coloring agents, flavouring agents, plasticizers,preservatives, suspending agents, emulsifying agents and spheronizationagents.

In still another embodiment of the present invention, the composition isformulated into dosage forms selected from a group comprising tablet,troches, lozenges, aqueous or oily suspensions, ointment, patch, gel,lotion, dentifrice, capsule, emulsion, creams, spray, drops, dispersiblepowders or granules, emulsion in hard or soft gel capsules, syrups,elixirs, phytoceuticals, nutraceuticals and food stuffs.

In still another embodiment of the present invention, the other relatedpharmaceutical activities are selected from a group comprisinginhibition of prolactin, muscle relaxation, role as precursor ofcatecholamines and decrease in sexual dysfunction and the side-effectscaused by anti-psychotic drugs.

The present invention also relates to a process of preparing apharmaceutical composition comprising trigonelline or its derivative(s)and 4-hydroxyisoleucine or its derivative(s), optionally along withexcipients(s), wherein the process comprising steps of:

-   -   1) extracting a clear solution containing trigonelline and        4-hydroxyisoleucine from plant source; and    -   2) optionally precipitating derivative(s) of trigonelline and        4-hydroxyisoleucine from the clear solution and obtaining said        composition.

In still another embodiment of the present invention, the concentrationof trigonelline or its derivative(s) ranges between 30% to 90% and theconcentration of 4-hydroxyisoleucine or its derivative(s) ranges between10% to 30%.

In still another embodiment of the present invention, the excipient(s)are selected from a group comprising granulating agents, binding agents,lubricating agents, disintegrating agents, sweetening agents, glidants,anti-adherents, anti-static agents, surfactants, anti-oxidants, gums,coating agents, coloring agents, flavouring agents, plasticizers,preservatives, suspending agents, emulsifying agents and spheronizationagents.

In still another embodiment of the present invention, the derivative(s)are selected from a group comprising hydrochloride derivatives, acetatederivatives, citrate derivatives, benzoate derivatives, salt derivativesand acid derivatives, preferably hydrochloride derivatives.

In still another embodiment of the present invention, the clear solutionis extracted from the plant Trigonella foenum graecum and/or Coffeaarabica comprising steps of:

-   -   a. flaking seeds of Trigonella and/or Coffea arabica;    -   b. defatting flaked Trigonella seeds using hexane solvent;    -   c. passing a solvent mixture of aliphatic alcohol and water        through the flaked seeds to extract a solvent containing        trigonelline and amino acid(s);    -   d. vacuum concentrating the solvent to obtain semisolid mass;    -   e. dissolving the semisolid mass in deionized water to obtain a        clear solution;    -   f. passing the clear solution of step (e) through an ion        exchange resin column to retain the amino acids and the        trigonelline;    -   g. eluting the column and concentrating the eluent to obtain        resultant mass;    -   h. drying the clear solution of the resultant mass to obtain a        free flowing powder; and    -   i. dissolving the powder in a solvent to obtain said clear        solution containing trigonelline and amino acid(s).

In still another embodiment of the present invention, the seeds areflaked to a size preferably of about 2 mm thickness.

-   -   In still another embodiment of the present invention, the        solvent mixture comprises an aliphatic alcohol and water in        ratio of 1:9 to 9:1, preferably 7:3.

In still another embodiment of the present invention, the aliphaticalcohol is ethanol.

In still another embodiment of the present invention, the column iseluted with aqueous or alcoholic solution of ammonia.

In still another embodiment of the present invention, the solvent isselected from a group comprising heterocyclic aromatic compounds,aliphatic compounds, ketones, cyanides, alcohols, nitrites, esters,ether and mixtures of one or more thereof.

In still another embodiment of the present invention, the solvent isethanol.

In still another embodiment of the present invention, the concentrationis carried at a temperature ranging from 40° C. to 80° C.

In still another embodiment of the present invention, the amino acid is4-hydroxyisoleucine.

The present invention also relates to a method of treating dopaminerelated diseases, said method comprising administering a therapeuticallyeffective amount of a pharmaceutical composition comprising trigonellineor its derivative(s) and 4-hydroxyisoleucine or its derivative(s),optionally along with excipients(s) in a subject in need thereof.

In still another embodiment of the present invention, the subject isanimal including human beings.

The present invention also relates to a method of treating ill effectscaused by prolactin, said method involves prolactin inhibition byadministering a therapeutically effective amount of a pharmaceuticalcomposition comprising trigonelline or its derivative(s) and4-hydroxyisoleucine or its derivative(s), optionally along withexcipients(s) in a subject in need thereof.

In still another embodiment of the present invention, the ill effectscaused by prolactin are selected from a group comprising infertility,polycystic ovary disease and increased lactation.

In still another embodiment of the present invention, the subject isanimal including human beings.

The present invention also relates to a method of treating side-effectscaused by dopamine receptor antagonists, said method comprisingadministering a therapeutically effective amount of a pharmaceuticalcomposition comprising trigonelline or its derivative(s) and4-hydroxyisoleucine or its derivative(s), optionally along withexcipients(s) in a subject in need thereof.

In still another embodiment of the present invention, the side-effectsare the movement disorders caused by blockage of dopamine receptor bydopamine receptor antagonists.

In still another embodiment of the present invention, the subject isanimal including human beings.

One embodiment of the present invention relates to the use of acomposition for the manufacture of a medicament with dopaminergicactivities, comprising trigonelline, it derivatives, 4hydroxyisoleucine, its derivatives and optionally with excipients(s).The trigonelline can be derived from botanical and animal sources. Thiscomposition is used for increasing dopamine concentration in the brainand therefore improving the conditions associated with low dopaminelevels such as parkinsons disease, movement disorders etc. Thiscomposition is used for activities related to prolactin inhibition,stopping lactation, muscle relaxation, decreases sexual dysfunction,increasing mental alertness and other dopamine related functions.Another aspect of this embodiment is that the composition havingdopaminergic activity is a selective Monoamine oxidase B inhibitor.Another aspect of the present invention is that the composition havingdopaminergic activity has no interaction with Tyramine containingsubstances and thus does not increase blood pressure when the subjectingests materials with high levels of tyramine.

Another embodiment of the present invention relates to the use of acomposition for the manufacture of a medicament with dopaminergicactivity which is capable of inhibiting prolactin levels in a subject inneed thereof. Still another aspect of the present embodiment is relatedto the use of the composition for the treatment of polycystic ovarydisease. Still another aspect of the present embodiment relates to theuse of the composition for the manufacture of a medicament for thetreatment of infertility. Still another aspect of the present embodimentis to manufacture a medicament for the regulation of the levels of humansex hormones.

Another embodiment of the present invention relates to the use of thecomposition having dopaminergic activity for the manufacture of amedicament to minimize the harm caused by dopamine receptor antagoniststhereby inducing immobility.

Another embodiment of the invention relates to a composition havingdopaminergic and pharmaceutical activity comprising trigonelline,derivatives of trigonelline, 4 hydoxyisoleucine, its derivatives andexcipients.

The composition of the present invention comprising trigonelline or itsderivative(s) and 4-hydroxyisoleucine or its derivative(s) optionallyalong with excipients(s) is herein also referred as test drug or testcompound or test drug composition in the specification.

The major advantage of the present embodiments of the present inventionis that the test drug is a Monoamine Oxidase-B inhibitor. Due to thisselectivity it does not elicit a response with dietary tyramine thuspreventing the “cheese reaction” which is a major side effect ofnon-selective MAO inhibitors. A second advantage is the fact that thiscomposition having dopaminergic activity can reduce the side effects ofantipsychotic drugs. Thirdly, this composition can also inhibitprolactin secretion which is a major advantage.

The present invention describes in detail the procedure for isolatingand purifying a chemical marker from such botanical as Trigonella foenumgreacu and Coffea arabica (botanical name). The chemical marker is thealkaloid Trigonelline and is extracted as its Hydrochloride, Acetate,Citrate, sulfonate, mesylate, hydroiodide Benzoate or a salt of an acidboth mineral and organic, but preferably as Hydrochloride. This purifiedextract is studied for its bioactivity in various classical animalmodels. A novel aspect of this compound is that it has a Dopamine likeactivity as confirmed by several specific animal experiments as perapproved protocols. Thus, it has been proved for the first time that thecompound trigonelline shows dopaminergic activity through our invention.

The brief summary of one embodiment is:

-   -   a. Trigonelline containing seeds for example fenugreek seeds or        Coffea arabica seeds are flaked to expose the inner core so as        to ensure effective defatting, extraction and processing.    -   b. Hexane solvent is passed through the fenugreek bed repeatedly        to achieve effective defatting of the fenugreek. This operation        need not be carried out for Coffea Arabica seeds.    -   c. The flaked seeds are loaded in a percolater and solvent        mixture comprising of an aliphatic alcohol and water are passed        through the layer to achieve effective extraction of the        Trigonelline and amino acids (4 hydroxyisoleucine) along with        Saponin.    -   d. The solvent is vacuum concentrated at lower temperatures to        ensure the integrity of the mass and the resultant mass is        dissolved in deionised water to get clear solution.    -   e. The clear solution thus obtained is passed through a strong        acid cation exchange resin in Gel form to retain the amino acids        and Trigonelline.    -   f. The column is washed free of all impurities and colors using        deionised water and the column is eluted with an aqueous        solution or alcoholic solution of ammonia with strength of 5N        concentration.    -   g. The eluted compound in the solvent elute is concentrated        under vacuum to remove the water and solvent and the resultant        mass is dissolved and filtered to get a clear solution.    -   h. The clear solution obtained is spray dried to get a free        flowing powder and maybe used as such.    -   i. The powder is re-dissolved in either isopropyl alcohol or        ethyl alcohol to get clear solution.    -   j. The purified extract is subjected to HPLC measurement to        confirm the assay.

Further, the clear alcoholic solution can optionally be subjected to agas stream of Hydrogen chloride to convert trigonelline and4-hydroxyisoleucine into their respective hydrochloride derivatives.

A purified extract of the above compound as Trigonelline and/or itsderivative and 4 hydroxyisoleucine and/or its derivatives isadministered to Swiss Albino mice as per a Haloperidol Protocol. Thisinduces Parkinson's symptoms. This extract reversed these symptoms in adose dependent manner confirming Dopaminergic or dopamine like activityof this extract.

A purified extract of the above compound as Trigonelline and/or itsderivative and 4 hydroxyisoleucine and/or its derivatives isadministered to Swiss Albino mice to examine the affect of this inOxotremorine Antagonism Mechanism. This confirms a mild Anticholinergicactivity, which makes this eminently suitable for Parkinson's treatment.

The Dopamine effect combined with mild Anticholinergic effect is thebest methodology for treatment of dopamine related disorders includingParkinson's disease. Parkinson's is not only brought about by depletionof Dopamine, but is also caused by the imbalance of Dopamine andAcetylcholine

Dopamine is a precursor for Epinephrine and Norepinephrine. Therefore,this compound can increase the concentration of Epinephrine and increasemental alertness and performance. Dopamine is an inhibitoryneurotransmitter. This can control the effects of Acetylcholine. Theproposed extract and compound can be used for the purpose of musclerelaxation in exercise physiology.

Dopaminergic substances reduce the hormone prolactin levels. Prolactinis implicated in sexual dysfunction. This compound can be used forinhibiting prolactin. Prolactin induces lactation in nursing mothers.Dopaminergic substances inhibit Prolactin. This compound can be used forstopping lactation.

In another embodiment of the present invention, the composition havingdopaminergic activity is derived from botanical sources.

1. Fenugreek seeds or any other seeds containing Trigonelline likeCoffea arabica seeds were flaked using roller flaking machine to a sizeof thickness varying between 1 mm to 4 mm size. The effective exposureof the inner core was achieved by flaking to a size preferably of 2 mmthickness. The flaked seeds were packed in an extractor fitted withbottom filter of suitable mesh size preferably 100 mesh to ensure thatthe seed meal is not allowed to move along with the solvent. Hexane isallowed to percolate through the packed seed layer.

2. The percolated solvent is recycled efficiently over period of 8 to 10hrs so that the resultant fenugreek meal is free of oils & lipids. Thisdelipidification procedure need not be carried out on Coffea arabicaseeds.

3. The Hexane extracted meal is re-extracted with a solvent mixturecomprising an aqueous aliphatic alcohol in a ratio of 1:9 to 9:1.Preferably 7:3 as the solvent. In the case of Coffea arabica seeds thealcohol solvent can be reduced to have a minimum composition of alcoholsay nine parts of water to one part of alcohol. The said alcohol may bemethyl alcohol, Ethyl alcohol, Isopropanol and preferably ethanol as thealcoholic solvent. The aqueous alcohol mixture is passed from top tobottom through the fenugreek layer in the percolater. The process ofrecycling the solvent was continued for a period of time ranging between8 hrs to 10 hrs preferably 8 hrs at room temperature. The clear extractfrom the bottom of the percolater is inspected visually for anysuspended particles and refiltered if necessary.

4. The clear filtrate is vacuum concentrated at a temperature rangingbetween 50° C. to 75° C. preferably at 55° C., to a pasty mass and thesolvent recovered. The paste is redissolved in deionised water to get aclear solution consisting of around 5% solid content.

5. The clear solution is passed through an Ion Exchange resin columnconsisting of a strong acid anion in gel form and eluted with 5N aqueousammonia solution. The column can also be eluted with aqueous alcoholicammonia solution preferably Ethanol, Isopropanol, or methanol in theratio of 1:1.

6. The desorbed solution is vacuum concentrated to 50% solid content andspray dried in a co-current spray dryer to powder. Optionally the powderobtained by the above manner is dissolved in ethyl alcohol or isopropylalcohol in the ratio of 1:20 of powder to alcohol ratio and is thenfiltered.

7. Optionally, the clear filtrate is cooled to low temperature between0° C. to 5° C. preferably at 0° C. and a dry stream of Hydrogen chloridegas is passed through it to precipitate Trigonelline and 4hydroxyisoleucine as their respective hydrochloride derivatives. Theprecipitated derivatives are filtered and washed clean of impurities anddried under vacuum between 60° C. to 90° C.

The invention is further elaborated with the help of following examples.However, these examples should not be construed to limit the scope ofthe invention.

EXAMPLE 1

1000 grams of fenugreek seeds having a moisture content less than 5%were flaked in a roller flaker to a thickness of 2 mm The flakedmaterial is stalked in a column having a bed height of 300 mm. 5 litersof hexane was passed through the layer of fenugreek and the eluentcollected from the bottom is recycled through the fenugreek layer for aperiod of 10 hrs at 35° C. After 10 hrs the fenugreek layer was drainedfree of hexane. Solvent mixture (8 liters) comprising of Isopropylalcohol and water in the ratio of 4:1 was passed through the layer for aperiod of 8 hrs at 35° C. by recycling the eluent. After 8 hrs thefenugreek bed is drained free of extracts and all the collected extractswere concentrated to semisolid mass under vacuum at 50° C.

The concentrated mass is redissolved in 5 liters of deionised water toget a clear solution. The clear aqueous solution was passed through acolumn containing 400 ml of strong acid cation exchange Gel type resinfor 2 hrs. TLC screening for the absence of Trigonelline checked on thecolumn eluent using a system consisting of n-Butanol:Acetic acid:Waterin the ratio of 12:8:4 as the mobile phase on silica Gel precoated plateF254 (1.05554.007) and observation under UV 254 nm. After saturation ofthe column the resin bed was washed free of colors and adheringimpurities using 4 liters of deionised water. The column is desorbedusing 800 ml of aqueous ammonia of 5N strength, at a rate of 400 ml perhour. The mixture eluted out is concentrated under vacuum at 45° C. to asemisolid mass.

The dried mass is redissolved in 150 ml of deionised water and filteredfree of insoluble. The solution is concentrated under vacuum at 50° C.to a solid content of 20% and spray dried in a co-current indirect hotair spray dryer under following conditions.

Inlet temperature: 160° C.Outlet temperature: 80° C.

Atomizer RPM: 12000

The yield is 9 gms. (The HPLC showed 25% Trigonelline & 35% amino acids)

The above material is redissolved in 250 ml of Ethyl alcohol, filteredthrough 41 Whatmann filter paper and cooled to 0° C. At that temperaturea dry stream of Hydrogen chloride gas is passed through this toprecipitate the Trigonelline hydrochloride. The precipitate was filteredout on filter paper and washed with cold ethyl alcohol and dried undervacuum at 60° C.

EXAMPLE 2

1000 grams of fenugreek seeds having a moisture content less than 5%were flaked in a roller flaker to a thickness of 2 mm The flakedmaterial is stalked in a column having a bed height of 300 mm. 5 litersof hexane was passed through the layer of fenugreek and the eluentcollected from the bottom is recycled through the fenugreek layer for aperiod of 10 hrs at 35° C. After 10 hrs the fenugreek layer was drainedfree of hexane. Solvent mixture (8 liters) comprising of Isopropylalcohol and water in the ratio of 4:1 was passed through the layer for aperiod of 8 hrs at 35° C. by recycling the eluent. After 8 hrs thefenugreek bed is drained free of extracts and all the collected extractswere concentrated to semisolid mass under vacuum at 50° C.

The concentrated mass is redissolved in 5 liters of deionised water toget a clear solution. The clear aqueous solution was passed through acolumn containing 400 ml of strong acid cation exchange Gel type resinfor 2 hrs. TLC screening for the absence of Trigonelline checked on thecolumn eluent using a system consisting of n-Butanol:Acetic acid:Waterin the ratio of 12:8:4 as the mobile phase on silica Gel precoated plateF254 (1.05554.007) and observation under UV 254 nm. After saturation ofthe column the resin bed was washed free of colors and adheringimpurities using 4 liters of deionised water. The column is desorbedusing 800 ml of aqueous ammonia of 5N strength, at a rate of 400 ml perhour. The mixture eluted out is concentrated under vacuum at 45° C. to asemisolid mass.

The dried mass is redissolved in 150 ml of deionised water and filteredfree of insoluble. The solution is concentrated under vacuum at 50° C.to a solid content of 20% and spray dried in a co-current indirect hotair spray dryer under following conditions.

Inlet temperature: 160° C.Outlet temperature: 80° C.

Atomizer RPM: 12000

The yield is 9 gms. (The HPLC showed 35% Trigonelline & 20%4-Hydroxyisoleucine)

EXAMPLE 3

1000 grams of fenugreek seeds having a moisture content less than 5%were flaked in a roller flaker to a thickness of 2 mm The flakedmaterial is stalked in a column having a bed height of 300 mm. 5 litersof hexane was passed through the layer of fenugreek and the eluentcollected from the bottom is recycled through the fenugreek layer for aperiod of 10 hrs at 35° C. After 10 hrs the fenugreek layer was drainedfree of hexane. Solvent mixture (8 liters) comprising of Ethyl alcoholand water in the ratio of 3.5:1 was passed through the layer for aperiod of 8 hrs at 35° C. by recycling the eluent. After 8 hrs thefenugreek bed is drained free of extracts and all the collected extractswere concentrated to semisolid mass under vacuum at 50° C.

The concentrated mass is redissolved in 5 liters of deionised water toget a clear solution. The clear aqueous solution was passed through acolumn containing 400 ml of strong acid cation exchange Gel type resinfor 2 hrs. TLC screening for the absence of Trigonelline checked on thecolumn eluent using a system consisting of n-Butanol:Acetic acid:Waterin the ratio of 12:8:4 as the mobile phase on silica Gel precoatedplateF254 (1.05554.007) and observation under UV 254 nm. Aftersaturation of the column the resin bed was washed free of colors andadhering impurities using 4 liters of deionised water. The column isdesorbed using 800 ml of aqueous ammonia of 5N strength at a rate of 400ml per hour. The mixture eluted out is concentrated under vacuum at 45°C. to a semisolid mass.

The dried mass is redissolved in 150 ml of deionised water and filteredfree of insoluble. The solution is concentrated under vacuum at 50° C.to a solid content of 20% and spray dried in a co-current indirect hotair spray dryer under following conditions.

Inlet temperature: 160° C.Outlet temperature: 80° C.

Atomizer RPM: 12000

The yield is 10 gms. (The HPLC showed 35% Trigonelline & 18%4-Hydroxyisoleucine amino acid)

The above material is redissolved in 250 ml of Ethyl alcohol, filteredthrough 41 Whatmann filter paper and cooled to 0° C. A dry stream ofHydrogen chloride gas is passed through this to precipitate theTrigonelline hydrochloride. The precipitate was filtered out on filterpaper and washed with cold ethyl alcohol and dried under vacuum at 60°C.

EXAMPLE 4

1000 grams of green Coffea Arabica seeds having moisture content lessthan 15% were flaked in a roller flaker to a thickness of 2 mm. Theflaked material is stalked in a column having abed height of 500 mm.Solvent mixture (8 liters) comprising of water and Ethyl alcohol in theratio of 9:1 was passed through the layer for a period of 8 hrs at 35°C. by recycling the eluent. After 8 hrs the Coffea Arabica bed isdrained free of extracts and all the collected extracts wereconcentrated to semisolid mass under vacuum at 50° C.

The concentrated mass is redissolved in 5 liters of deionised water toget a clear solution. The clear aqueous solution was passed through acolumn containing 400 ml of strong acid cation exchange Gel type resinfor 2 hrs. TLC screening for the absence of Trigonelline checked on thecolumn eluent using a system consisting of n-Butanol:Acetic acid Waterin the ratio of 12:8:4 as the mobile phase on silica Gel precoatedplateF254 (1.05554.007) and observation under UV 254 nm. Aftersaturation of the column the resin bed was washed free of colors andadhering impurities using 4 liters of deionised water. The column isdesorbed using 800 ml of aqueous ammonia of 5N strength at a rate of 400ml per hour. The mixture eluted out is concentrated under vacuum at 45°C. to a semisolid mass.

The dried mass is redissolved in 150 ml of deionised water and filteredfree of insoluble. The solution is concentrated under vacuum at 50° C.to a solid content of 20% and spray dried in a co-current indirect hotair spray dryer under following conditions.

Inlet temperature: 160° C.Outlet temperature: 80° C.

Atomizer RPM: 12000

The yield is 5 grams. (The HPLC showed 60% Trigonelline & remainingamino acids)

The above material is redissolved in 200 ml of Ethyl alcohol, filteredthrough 41 whatmann filter paper and cooled to 0° C. a dry stream ofHydrogen chloride gas is passed through this to precipitate theTrigonelline hydrochloride. The precipitate was filtered out on filterpaper and washed with cold ethyl alcohol and dried under vacuum at 60°C.

EXAMPLE 5

1000 grams of green Coffea Arabica seeds free of parchment is pulverizedin a Commuting mill to a 100% passing through a 20 mesh size. The brokenseeds are boiled with 6 liters of deionised water at 95 to 100° C. for 4hrs and filtered clear of all insoluble through filter cloth. The clearsolution is cooled to room temperature and passed through an ionexchange resin column containing 500 ml of freshly regenerated strongacid cation exchange resin over a period of 3 hrs. The bottom eluent wasmonitored for the absence of Trigonelline using TLC system comprising ofN-Butanol:acetic acid:water in the ratio of 10:8:5 and visualizationthrough UV at 254 nm.

The column was washed free of all colors and impurities using 5 litersof Dematerialized water. The column is eluted with 600 ml of 6% ammoniasolution and checked for the completion elution using the TLC systemmentioned previously. The eluted liquid is concentrated at 50° C. undervacuum to a paste. The paste is triturated with 100 ml of 20%Hydrochloric acid gas in Isopropyl alcohol at 75° C. for 3 hrs andcooled to room temperature. The resultant precipitate is filtered andwashed free of colours with 500 ml of isopropyl alcohol. The solid isdried at 80° C. under vacuum to get 10 grams of free flowing powder.

The following examples were conducted with the novel compositioncomprising trigonelline and 4 HI as well as trigonelline derivative(hydrochloride) and 4 HI derivative (hydrochloride).

EXAMPLE 6 Haloperidol Induced Catalepsy in Mice

Haloperidol is neuroleptic agent that blocks the Dopamine D2 receptor inthe brain. This precipitates the extra-pyramidal side effects which canbe measured by the “Bar Test for catalepsy in mice”. Catalepsy in miceis defined as a failure to correct an externally imposed unusual postureover a prolonged period of time. This catalepsy in mice is comparable tothe akinesia, muscle rigidity and tremors seen in subjects withParkinson's disease. Haloperidol induced catalepsy can be reversed ifdopaminergic drugs that supply dopamine to the striatum of the brainsince it increase competitive antagonism.

Procedure: Swiss Albino mice of either sex weighing 23-28 g are used.Catalepsy was induced by Haloparidol (0.5 mg/kg i.p.) and assessed bybar test up to 3 hrs. Six animals are dosed with the saline, test drugand the standard intraperitonially. The animals are placed intranslucent plastic boxes with a wooden dowel mounted horizontally 2.5cm from the floor of the box. The animals are allowed to adapt to thebox for 2 min. Then, each animal is grasped gently around the shouldersand under the forepaws and placed carefully on the dowel. The amount ofthe time spent with at least one forepaw on the bar is determined. Whenthe animal removes its paws, the time is recorded and the mice arerepositioned on the bar. Three trials are conducted for each animal at30, 60, 120 and 360 min, with 6 animals in each group.

The test drug has shown significant dose dependant response in reducingcatalepsy (FIG. 1). The effects of the standard drug L-Dopa at a dosageof 10 mg/kg was found to be more effective than the test drug at adosage of 100 mg/kg. Although this difference is significant, the testdrug proved to be fast acting and devoid of the “ON-OFF” action presentin standard drugs. Also the standard drug showed a decline in thereduction of catalepsy after the initial effect on the catalepsy. Thisconfirms Dopaminergic action of the test drug (FIG. 1). Thus it can beseen that the test drug is reversing the induced symptoms of Parkinsonby Haloparidol.

The reversal of haloperidol induced catalepsy confirms the ability ofthe test drug composition to minimize the side effects caused byhaloperidol which is a dopamine receptor antagonist. Hence this showsthat the drug is a dopaminergic agent which can be used to minimize theeffects of dopamine receptor antagonists including anti-psychotic drugs.

EXAMPLE 7 Oxotremorine Antagonism

Oxotremorine is a cholinergic drug which is a muscarine agonist andinduces parkinsonism-like signs such as tremors, ataxia, spasticity,salivation, lacrimation and hypothermia. Oxotremorine is a cholinergicdrug, which induces excessive tremors in mice. If a drug is havinganti-cholinergic property like atropine the tremors will be decreased.

Procedure: Groups of 6-10 male NMRI mice weighing 18-22 g are used. Theyare dosed orally with the test compound or the standard (5 mg/kgbenezatropine mesilate) 1 hour prior to the administration of 0.5 mg/kgoxotremorine. Tremor is scored after oxotremorine dosage in periods of 5min for 1 hour.

After the administration of 0.5 mg/kg of Oxotremorine, the tremorsstarted within 15 mins and were sustained for 30 mins.

Parameters:

Salivation and Lacrimation 30 mins after oxotrmorine Tremor Scoreinjection Absent 0 Absent 0 Slight 1 Slight 1 Medium 2 Medium 2 Severe 3Severe 3No. of animals used in each group n=6

Tremor Score

Tremor Tremor Tremor Tremor score score score score 5 15 30 45 Categoryminutes minutes minutes minutes Control group only oxytremorine 3.0 2.82.7 2.6 n = 6 Test compound group 30 mg/kg 2.7 2.6 2.5 2.5 andoxytremorine n = 6 Test compound group 100 mg/kg 1.6 1.6 1.8 1.9 andoxytremorine n = 6 Test compound group 200 mg/kg 1.6 1.6 1.7 1.6 andoxytremorine n = 6 Positive control atropine 5 mg/kg 0.9 0.9 1.0 1.3 andoxytremorine n = 6

Test compound has shown significant activity by decreasing the tremorscore at 100 mg/kg and 200 mg/kg dose. This activity is consistent andis sustained up to 45 minutes. The activity at 30 mg/kg is low. Positivecontrol atropine has the test activity but decreases with time. Thus thetest drug is reversing Parkinson's symptoms by mild AnticholinergicActivity.

Salivation and Lacrimation Score

Salivation score at Lacrimation score Category 30 minutes at 30 minutesControl group only oxytremorine n = 6 3.0 2.9 Test compound at 30 mg/kg2.5 2.6 Test compound at 100 mg/kg 1.6 1.7 Atropine 0.8 0.6

Test compound has shown reduction in salivation score. However, it isnot as powerful as atropine thereby indicating mild Anticholinergiceffect. The lacrimation also gets reduced. However, it is not aspowerful as Atropine.

Atropine 1 mg/kg and the test drug at 100, 200 and 400 mg/Kg causesignificant decrease in severity of tremors (FIG. 2) and isinsignificant at dose 30 mg/kg. The drug is showing maximum effect at 30min and it is started reversing after 45 min. Hence the test drug hasanti-cholinergic property at very high doses.

EXAMPLE 8 6-Hydroxydopamine Model

6-Hydroxydopamine (6-OHDA) is a neurotoxin which causes a unilaterallesion of the dopaminergic nigrostriatal pathway that induceshypersensitivity of the post synaptic dopaminergic receptor in thestriatum of the lesioned side. An indirect acting compound likeamphetamine is administered the mice rotate toward the lesioned side(ipsilateral) as opposed to when a direct acting dopaminergic drug isadministered which causes then to rotate contra laterally. Therefore,this test can be used for the study of central dopamine function and theevaluation of dopamine antagonists and agonists, particularly theactivity of novel anti-parkinsonian drugs. This test clearlydistinguishes drugs with predominantly dopamine receptor agonistactivity from those with predominantly dopamine releasing activity ofthe drug.

Procedure: Male Wistar mice weighing 200-250 grams at the time ofsurgery are used. They are housed individually in a controlledenvironment with free access to food and water. The animals areanaesthetized with sodium pentobarbital. The head is placed in astereotaxic device (DKI 900) and positioned according to the atlas ofKonig and Klippel. After a sagittal cut is made in the skin of theskull, a 2 mm wide hole is drilled with an electrical trepan drill. Careis taken not to lesion the meninges. A 30 gauge stainless-steel cannulaconnected to a Hamilton syringe is aimed at the anterior zona compactaof the substantia nigra (coordinates anterior 1.88 mm, lateral 2.0 mmand dorso-ventral—8.2 mm from instrument zero). A total of 8 μg of 6-HADin 4 γ/L of saline is injected at a rate of 1 γ/L/min. After theintra-cranial injection, the wound is closed.

The animal is allowed several weeks for recovery and for development ofthe lesion. Specially constructed opaque plastic spheres attached tosolid state programming equipment serve as test chambers. The number offull turns, either ipsilateral or contra lateral to the lesion, arerecorded on an automatic printout counter every 15 min for one or twohours test sessions. To determine the control values for ipsilateralturning, each subject is administered 2.5 mg/kg of d amphetamine andimmediately placed in the circling chamber for 2 hours Control valuesfor contra lateral circling are determined by injecting apomorphine at 1mg/kg s.c. and recording the rat's circling for 1 hour. Test compoundsare given i.p or sc. And the animals placed into the circling chambers.Circling is recorded over a 1 hour period. This experiment is conductedin 30 animals and the average is represented in the table

Drug & Dosage Contra-lateral Rotation Ipsilateral Rotation Sterile Water1 0.33 Test Drug (10 mg/kg) 0.67 5.33 Test Drug (30 mg/kg) 0.83 30.67Test Drug (100 mg/kg) 0.35 10.4 Apomorphine (0.3 mg/kg) 169.33 0.67L-Dopa (10 mg/kg) 45.67 0.83

The test drug induced significant ipsilateral rotations at dose 30 mg/kg(P<0.001) and 10 mg/kg (P<0.05). This test mimics dopamine depletion andconsequently Parkinson's disease. Anti-Parkinson's compounds may havecontra-lateral or ipsilateral rotation. Drugs like Amphetamine induceipsilateral rotation. Whereas drugs like L-Dopa, Apomorphine,Bromocriptine induce contralateral rotation. Monoamine Oxidase Binhibitors like Selgiline induces ipsilateral rotation. COMT inhibitorsinduce contra-lateral rotation.

The test drug behaves like Amphetamine or Monoamine Oxidase (MAO-B)inhibitor. Hence the test drug may have the dopamine releasing propertythat is significant as compared to control at these doses.

This model is an important one to determine whether a compound is adopaminergic one or one that acts on the dopamine receptors. Theipsilateral rotation with the test compound shows its dopaminergicactivity. Unlike the current class of drugs which show a contralateralrotation the test compound is a dopaminergic agent and not a receptoragonist.

This experiment proves the exclusive dopaminergic activity of the testdrug. Hence this dopaminergic composition can find applications relatedto increase of levels of dopamine. Increased levels of dopamine have aninhibitory effect on prolactin levels. Increased prolactin levels areone of the causes of PCOS and infertility. This dopaminergic compoundinhibits prolactin levels by increasing dopamine levels.

This dopaminergic compound also finds applications as a muscle relaxant.

EXAMPLE 9 Testing the Effects of the Test Drug on MPTP Treated Mice

This test determines the extent of effect on the locomotor activity ofMPTP (Methyl Phenyl TetraPyridine) treated mice when they arepre-treated and post-treated with the test drug.

When MPTP is administered through the systemic route it causes transientimpairment of the dopamine system function. This test helps to determinethe pathophysiology of neurodegenerative processes as well as theeffects of neuro-trophic and neuro-protective agents.

MPTP significantly decreases the locomotor activity of the mice. Thetest drug's efficiency is measured based on the percentage increase inthe motor activity in the MPTP treated mice.

The locomotor activity is measured in terms of:

1. Spontaneous Motor Activity

Treatment Mean ± SEM % Increase Untreated 868.166 ± 17.377 — MPTP290.166 ± 18.679^(###) — Test Drug (Pre): 564.166 ± 24.106*** 94.43%Prophylactic Test Drug (Post): 280.500 ± 23.891^(ns) −3.33% Therapeutic

Pre-treatment of the mice with the test drug significantly reduced theeffect of MPTP. Although the pre-treatment gave good results, thetreatment of the mice with the test drug, post the treatment with MPTPdid not show an increase in the motor activity.

2. Number of Squares Crossed in an Open Field

Treatment Mean ± SEM % Increase Untreated 465.500 ± 18.005 — MPTP122.333 ± 8.151^(###) — Test Drug (Pre): 250.166 ± 12.908*** 104.49%Prophylactic Test Drug (Post): 143.166 ± 12.475^(ns) 17.03% Therapeutic

The pre-treatment with the test drug drastically increased the number ofsquares crossed by the mice, while post-treatment with the test drug didnot show a very significant increase.

3. Total Distance Traveled in an Open Field

Treatment Mean ± SEM % Increase Untreated 698.250 ± 27.008 — MPTP183.500 ± 12.227^(###) — Test Drug (Pre): 375.250 ± 19.363 *** 104.49%Prophylactic Test Drug (Post): 214.750 ± 18.713^(ns) 17.03% Therapeutic

The pre-treatment with the test drug drastically increased the distancetraveled by the mice, while post-treatment with the test drug did notshow a very significant increase.

4. Total Movement Time in an Open Field

Treatment Mean ± SEM % Increase Untreated 233.420 ± 7.322 — MPTP 217.330± 8.979 — Test Drug (Pre): 235.350 ± 9.001 8.29% Prophylactic Test Drug(Post):  242.790 ± 13.503 11.71% Therapeutic

No significant time change was observed during the pre/post-treatmentwith the test drug on the MPTP treated mice.

5. Average Speed in an Open Field

Treatment Mean ± SEM % Increase Untreated 2.999 ± 0.124 — MPTP 0.846 ±0.051 — Test Drug (Pre): 1.595 ± 0.059*** 88.53% Prophylactic Test Drug(Post): 0.890 ± 0.079^(ns) 5.2% Therapeutic

Pre-treatment of the mice with the test drug significantly increased theaverage speed of the mice, while post-treatment showed no increase inthe speed.

Thus by the above experiments it is observed that the compositionprepared by the above mentioned process has potent dopaminergicactivity, and is an MAO inhibitor. This optimum dosage of the drug doesnot show anti-cholinergic activity, which is seen at very high doses ofthe drug.

EXAMPLE 10 Effect of Test Drug on Tyramine Potentiation

Non-selective MAO inhibitors when used as neuropsychiatric drugs cause acondition called tyramine potentiation. Tyramine is an amino acid whichis a precursor for the mono amine noradrenaline. Monoamine oxidase-A(MAO-A) is an enzyme which prevents the conversion of tyramine tonoradrenaline. Thus in the presence of drugs which act like MAO-Ainhibitors the levels of noradrenaline is high. Most fermented foods,like cheese, wine etc, have a high percentage of tyramine. Thus whenfoods like these are ingested by a subject who is consuming MAO-Ainhibitors, there is a sudden surge in the tyramine level andsubsequently the level of noradrenaline also rises. This sudden increasein the level of noradrenaline drastically increases the blood pressureand can lead to fatal consequences.

The tyramine potentiation test is conducted to determine the selectivityof the test drug for MAO-A/B. For an accurate determination of thistest, the study was carried out in an acute and chronic environment ofthe drug.

Acute Study: In the acute study the male Wistar rats (n=5) were takenwere anesthetized by injecting urethane solution (1.25 g/kg, i.p.). Bodytemperature was maintained at 37° C. and the trachea was cannulated tomaintain airways. (Blood pressure) instruments inserted in the canulasto the left carotid artery and the jugular vein for blood pressure (BP)monitoring and drug administration, respectively. The arterial catheterwas connected to the pressure transducer to measure the blood pressureusing four channel physiological recorder systems. The effects of thetest drug (30 mg/kg p.o.) to the Tyramine (5 mg/kg i.v.) were recorded(FIG. 3). The study conducted has 3 groups:

Group 1: Normal Group 2: Tyramine+Test Drug

Group 3: Tyramine aloneChronic Study: The male Wistar rats (n=5) were administered with testdrug (30 mg/kg p.o.) for one month. Body temperature was maintained at37° C. and the trachea was cannulated to maintain airways. Instrumentsinserted in the canulas to the left carotid artery and the jugular veinfor blood pressure (BP) monitoring and drug administration,respectively. The arterial catheter was connected to the pressuretransducer to measure the blood pressure using four channelphysiological recorder systems. The effects of the test drug (30 mg/kgp.o.) to the Tyramine (5 mg/kg i.v.) were recorded (FIG. 4).The study conducted has 3 groups:

Group 1: Normal Group 2: Tyramine+Test Drug

Group 3: Tyramine alone

In both the acute and the chronic study, the test drug did not show anyraise in blood pressure thus establishing that these are not MAO-Ainhibitors. Tyramine causes a slight increase in blood pressure, thecurrent class of MAOIs usually cause a drastic increase in bloodpressure (tyramine potentiation). Hence from the graphs seen in theAcute and Chronic Study, the test drug does not potentiate an increasein blood pressure.

Hence the test drug is deemed to be a MAO-B inhibitor, which does notcause tyramine potentiation and has no interaction with tyramineingested from foods in the diet. This is a major advantage of the testdrug over the existing class of drugs.

EXAMPLE 11 Evaluate an in Enzyme Assay of the Test Drug

The inhibition curves for this experiment are shown in FIG. 5. Theseenzyme assays were carried out as per the references

-   -   Youdim M B and Finberg J P (1991)    -   New directions in monoamine oxidase A and B selective inhibitors        and substrates. Biochem Pharmacol. 41(2): 155-162    -   Urban P, Andersen J K, Hsu H P and Pompon D (1991)    -   Comparative membrane locations and activities of human monoamine        oxidases expressed in yeast. FEBS Lett. 286(1-2): 142-146.

This experiment measures the ability of the test drug composition F-1 inthe inhibition of the enzyme monoamine oxidase. MAOs are an enzymes thatcatalyze the oxidation of monoamines. In humans there are two types ofMAOs—MAO A and MAO B. Both these enzymes are found in the neurons andastroglia as well as outside the CNS.

Outside the CNS MAOs are found:MAO-A: Liver, gastrointestinal tract and placenta

MAO-B: Platelets

Both MAOs are also vital to the inactivation of monoaminergicneurotransmitters, for which they display different specificities.

-   -   MAO-A: Breakdown of Serotonin, norepinephrine (noradrenaline),        and epinephrine (adrenaline).    -   MAO-B: Breakdown of Phenethylamine.

Both forms of MAOs break down dopamine.

The present classes of MAO inhibitors usually have an interaction withfoods that have high tyramine levels like cheeses, pickled foods,chocolates, beer, wine and certain meats. The interaction of tyraminewith MAOIs can cause a dangerously high increase in blood pressure,which can lead to a stroke.

The response curves that illustrate the selective inhibition of MAO-B bythe test compound is shown in FIG. 5. This graph illustrates theinhibition of MAO-B by the test drug which is very useful in thetreatment of dopamine related diseases including Parkinson's disease.

The tyramine potentiation experiment conducted in Example 10 shows thatthe test drug does not have an increasing effect on blood pressure andhence is safe for use in a subject in need thereof.

EXAMPLE 12

For Human doses

-   -   1) For therapeutic application of management of Parkinsons        disease a human dose of 0.5 mg per kg to 20 mg per kg daily as a        single dose or triturated into three equal doses per day.    -   2) For therapeutic dose in decreasing the level of prolactin        which is implicated in loss of libido and sexual dysfunction, a        daily recommended dose of 0.5 mg per kg of body weight to 25 mg        per kg of body weight as a single dose or triturated into 3        equally divided doses.    -   3) Therapeutic dose for stopping lactation in nursing mothers        0.5 mg per kg to 20 mg per kg of body weight daily.    -   4) For muscle relaxation in exercise physiology the recommended        dose is 0.25 mg per kg to 17 mg per kg of body weight.    -   5) For mental alertness and performance enhancement the        recommended daily dose is 0.25 mg per kg to 15 mg per kg of body        weight.

1. A pharmaceutical composition having dopaminergic activity and otherrelated pharmaceutical activities comprising trigonelline or itsderivative(s) and 4-hydroxyisoleucine or its derivative(s), optionallyalong with excipients(s).
 2. The pharmaceutical composition as claimedin claim 1, wherein the concentration of trigonelline or itsderivative(s) ranges between 30% to 90% and the concentration of4-hydroxyisoleucine or its derivative(s) ranges between 10% to 30%. 3.The pharmaceutical composition as claimed in claim 1, wherein thetrigonelline is obtained from plant or animal source.
 4. Thepharmaceutical composition as claimed in claim 1, wherein thetrigonelline is obtained from Trigonella foenum graecum and Coffeearabica.
 5. The pharmaceutical composition as claimed in claim 1,wherein the derivative(s) of trigonelline are selected from a groupcomprising hydrochloride derivatives, acetate derivatives, citratederivatives, benzoate derivatives, salt derivatives and acidderivatives, preferably hydrochloride derivatives.
 6. The pharmaceuticalcomposition as claimed in claim 1, wherein the 4-hydroxyisoleucine isobtained from plant source, preferably Trigonella foenum graecum.
 7. Thepharmaceutical composition as claimed in claim 1, wherein thederivative(s) of 4-hydroxyisoleucine are selected from a groupcomprising hydrochloride derivatives, acetate derivatives, citratederivatives, benzoate derivatives, salt derivatives and acidderivatives, preferably hydrochloride derivatives.
 8. The pharmaceuticalcomposition as claimed in claim 1, wherein the excipients(s) areselected from a group comprising granulating agents, binding agents,lubricating agents, disintegrating agents, sweetening agents, glidants,anti-adherents, anti-static agents, surfactants, anti-oxidants, gums,coating agents, coloring agents, flavouring agents, plasticizers,preservatives, suspending agents, emulsifying agents and spheronizationagents.
 9. The pharmaceutical composition as claimed in claim 1, whereinthe composition is formulated into dosage forms selected from a groupcomprising tablet, troches, lozenges, aqueous or oily suspensions,ointment, patch, gel, lotion, dentifrice, capsule, emulsion, creams,spray, drops, dispersible powders or granules, emulsion in hard or softgel capsules, syrups, elixirs, phytoceuticals, nutraceuticals and foodstuffs.
 10. The pharmaceutical composition as claimed in claim 1,wherein the other related pharmaceutical activities are selected from agroup comprising inhibition of prolactin, muscle relaxation, role asprecursor of catecholamines and decrease in sexual dysfunction and theside-effects caused by anti-psychotic drugs.
 11. A process of preparinga pharmaceutical composition comprising trigonelline or itsderivative(s) and 4-hydroxyisoleucine or its derivative(s), optionallyalong with excipients(s), wherein the process comprising steps of: a)extracting a clear solution containing trigonelline and4-hydroxyisoleucine from plant source; and b) optionally precipitatingderivative(s) of trigonelline and 4-hydroxyisoleucine from the clearsolution and obtaining said composition.
 12. The process as claimed inclaim 11, wherein the concentration of trigonelline or its derivative(s)ranges between 30% to 90% and the concentration of 4-hydroxyisoleucineor its derivative(s) ranges between 10% to 30%.
 13. The process asclaimed in claim 11, wherein the excipient(s) are selected from a groupcomprising granulating agents, binding agents, lubricating agents,disintegrating agents, sweetening agents, glidants, anti-adherents,anti-static agents, surfactants, anti-oxidants, gums, coating agents,coloring agents, flavouring agents, plasticizers, preservatives,suspending agents, emulsifying agents and spheronization agents.
 14. Theprocess as claimed in claim 11, wherein the derivative(s) are selectedfrom a group comprising hydrochloride derivatives, acetate derivatives,citrate derivatives, benzoate derivatives, salt derivatives and acidderivatives, preferably hydrochloride derivatives.
 15. The process asclaimed in claim 11, wherein the clear solution is extracted from theplant Trigonella foenum graecum and/or Coffea arabica comprising stepsof: a. flaking seeds of Trigonella and/or Coffea arabica; b. defattingflaked Trigonella seeds using hexane solvent; c. passing a solventmixture of aliphatic alcohol and water through the flaked seeds toextract a solvent containing trigonelline and amino acid(s); d. vacuumconcentrating the solvent to obtain semisolid mass; e. dissolving thesemisolid mass in deionized water to obtain a clear solution; f. passingthe clear solution of step (e) through an ion exchange resin column toretain the amino acids and the trigonelline; g. eluting the column andconcentrating the eluent to obtain resultant mass; f. drying the clearsolution of the resultant mass to obtain a free flowing powder; and g.dissolving the powder in a solvent to obtain said clear solutioncontaining trigonelline and amino acid(s).
 16. The process as claimed inclaim 15, wherein the seeds are flaked to a size preferably of about 2mm thickness.
 17. The process as claimed in claim 15, wherein thesolvent mixture comprises an aliphatic alcohol and water in ratio of 1:9to 9:1, preferably 7:3.
 18. The process as claimed in claim 15, whereinthe aliphatic alcohol is ethanol.
 19. The process as claimed in claim15, wherein the column is eluted with aqueous or alcoholic solution ofammonia.
 20. The process as claimed in claim 15, wherein the solvent isselected from a group comprising heterocyclic aromatic compounds,aliphatic compounds, ketones, cyanides, alcohols, nitriles, esters,ether and mixtures of one or more thereof.
 21. The process as claimed inclaim 15, wherein the solvent is ethanol.
 22. The process as claimed inclaim 15, wherein the concentration is carried at a temperature rangingfrom 40° C. to 80° C.
 23. The process as claimed in claim 15, whereinthe amino acid is 4-hydroxyisoleucine.
 24. A method of treating dopaminerelated diseases, said method comprising administering a therapeuticallyeffective amount of a pharmaceutical composition comprising trigonellineor its derivative(s) and 4-hydroxyisoleucine or its derivative(s),optionally along with excipients(s) in a subject in need thereof. 25.The method as claimed in claim 24, wherein the subject is animalincluding human beings.
 26. A method of treating ill effects caused byprolactin, said method involves prolactin inhibition by administering atherapeutically effective amount of a pharmaceutical compositioncomprising trigonelline or its derivative(s) and 4-hydroxyisoleucine orits derivative(s), optionally along with excipients(s) in a subject inneed thereof.
 27. The method as claimed in claim 26, wherein the illeffects caused by prolactin are selected from a group comprisinginfertility, polycystic ovary disease and increased lactation.
 28. Themethod as claimed in claim 26, wherein the subject is animal includinghuman beings.
 29. A method of treating side-effects caused by dopaminereceptor antagonists, said method comprising administering atherapeutically effective amount of a pharmaceutical compositioncomprising trigonelline or its derivative(s) and 4-hydroxyisoleucine orits derivative(s), optionally along with excipients(s) in a subject inneed thereof.
 30. The method as claimed in claim 29, wherein theside-effects are the movement disorders caused by blockage of dopaminereceptor by dopamine receptor antagonists.
 31. The method as claimed inclaim 29, wherein the subject is animal including human beings.